Israeli company donating more medication for dealing with coronavirus
The global Israeli company Teva Pharmaceutical Industries is donating more than 6 million doses of hydroxychloroquine sulfate tablets to hospitals across the United States to meet the urgent demand for the medicine as an investigational target to treat COVID-19.In a crisis, you quickly find out who your friends are and Israel is responding with help in dealing with it. Israel also has people working on a vaccine for the coronavirus.
Hydroxychloroquine sulfate is approved by the US Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus, and rheumatoid arthritis.
The drug is not approved for use in treating COVID-19. However, it is under investigation for efficacy against the novel coronavirus and has been requested by US government officials to be made available for testing purposes.
“Immediately upon learning of the potential benefit of hydroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately,” said Brendan O’Grady, Teva Executive Vice President, North America Commercial.
“We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost.”
O’Grady said that additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from its ingredient supplier.